190850-37-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-CHLOROBENZOYL)PYRIDINE is used as an intermediate in the synthesis of α7 nicotinic acetylcholine receptor agonists. These agonists are important for the treatment of various neurological and cognitive disorders, such as Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The compound's unique structure allows for the development of drugs that can selectively target and modulate the α7 nicotinic acetylcholine receptor, leading to improved therapeutic outcomes.
Additionally, 2-(4-CHLOROBENZOYL)PYRIDINE is used as an intermediate in the preparation of glycine transporter inhibitors. These inhibitors play a significant role in the treatment of various central nervous system (CNS) disorders, including chronic pain, anxiety, and epilepsy. By inhibiting the glycine transporter, these drugs can enhance the inhibitory effects of glycine in the CNS, leading to a reduction in neuronal excitability and an improvement in the symptoms associated with these conditions.

InChI:InChI=1/C12H8ClNO/c13-10-6-4-9(5-7-10)12(15)11-3-1-2-8-14-11/h1-8H

Upstream product

• 4385-62-0 4-(pyridin-2-yl)benzoic acid 
• 4467-06-5 2-(4-methylphenyl)pyridine 
• 109-04-6 2-bromo-pyridine 
• 14047-29-1 4-carboxyphenylboronic acid 

Downstream Products

• 717116-23-9 N-(4-tert-butyl-phenyl)-4-pyridin-2-yl-benzamide 
• 1175529-94-8 methyl 2-hydroxy-3-(4-(pyridin-2-yl)benzamido)benzoate 
• 1338816-26-4 C₂₃H₂₁F₂N₃O₂ 
• 1338816-27-5 C₂₅H₂₃F₂N₃O₃ 
• 1338816-28-6 C₂₅H₂₃F₂N₃O₃ 
• 1338816-29-7 C₂₄H₂₃F₂N₃O₂ 
• 1332585-85-9 3-(5-(4-(pyridin-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)-9-hexyl-9H-carbazole 
• 1380546-82-6 N-methoxy-4-(pyridin-2-yl)benzamide 
• 190850-38-5 C₁₄H₁₄N₂O₂ 

Relevant academic research and scientific papers

Ammonia as Ultimate Amino Source in Synthesis of Primary Amines via Nickel-Promoted C-H Bond Amination

The direct use of ammonia in transition-metal promoted C-H bond amination for the synthesis of primary amines is considered to be one of the major challenges in synthetic organic chemistry. Herein, we report that such transformation can be successfully ac

Highly selective mild stepwise allylation of N-methoxybenzamides with allenes

An efficient Rh(III)-catalyzed stepwise ortho allylation of N-methoxybenzamides 1 with polysubstituted allenes is reported. This C-H functionalization involving allenes is conducted under very mild conditions (-20 °C or room temperature) and compatible wi

Novel yellow phosphorescent iridium complexes containing a carbazole-oxadiazole unit used in polymeric light-emitting diodes

Yellow iridium complexes Ir(PPOHC)3 and (PPOHC) 2Ir(acac) (PPOHC: 3-(5-(4-(pyridin-2-yl)phenyl)-1,3,4-oxadiazol-2-yl) -9-hexyl-9H-carbazole) were synthesized and characterized. The Ir(PPOHC) 3 complex has good thermal stability with 5% weight-reduction occurring at 370 °C and a glass-transition temperature of 201 °C. A polymeric light-emitting diode using the Ir(PPOHC)3 complex as a phosphorescent dopant showed a luminance efficiency of 16.4 cd/A and the maximum external quantum efficiency of 6.6% with CIE coordinates of (0.50, 0.49). A white polymeric light-emitting diode was fabricated using Ir(PPOHC)3 which showed a luminance efficiency of 15.3 cd/A, with CIE coordinates of (0.39, 0.44). These results indicate that the iridium complexes containing a linked carbazole-oxadiazole unit are promising candidates in high-efficiency electroluminescent devices.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Azapeptide derivatives as HIV protease inhibitors

This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds with α7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders.

Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists

The dopamine D3 receptor subtype has been targeted as a potential neurochemical modulator of the behavioral actions of psychomotor stimulants, such as cocaine. Previous synthetic studies provided structural requirements for high affinity bindin